Home ▸ News

Ischemix Elects Peter G. Milner, MD to Board of Directors

August 12, 2015

Ischemix, Inc., a clinical-stage pharmaceutical company focused on hospital-acquired kidney and cardiac injury, announced today that Peter G. Milner, MD has been elected to its Board of Directors. David A. DeWahl, Jr., President and CEO of Ischemix said "Dr. Milner's breadth of experience in pharmaceutical development and regulatory approvals will enhance the progress of our leading drug candidate and pipeline toward regulatory and clinical acceptance. His participation on our Board is a real vote of confidence in our drug candidates and approach."

Dr. Milner is Chairman and co-founder of Armetheon, a private company conducting a Phase 3 trial of a novel oral anticoagulant. Previously he was CEO of Heart Metabolics, a private company addressing hypertrophic cardio-myopathy. Dr. Milner also co-founded Optivia Biotechnology, a leading transporter biology company as well as ARYx Therapeutics, where he served as CEO and President. Previously he co-founded cardiovascular company CV Therapeutics. Dr. Milner is a board certified cardiologist, a Fellow of the American College of Cardiology, and co-inventor on 50 patents and author of many original papers. He serves as adjunct clinical faculty at Stanford University and as a board member of the California Life Sciences Association.

"Dr. Milner, who will also join Ischemix' eminent Clinical Advisory Board, will bring impressive skills to guide this first direct cytoprotective drug into the marketplace" said Dr. Reinier Beeuwkes, Chairman of the Company. "Response to an unmet medical need and strong patent protection are not enough. Superb talent and experience make the critical difference."

Latest News

August, 2023

Ischemix, Inc. Completes Successful Phase 1 Trial of Novel Compound to Treat Traumatic Brain Injury (TBI); Preparing for Conduct of Phase 2 Trial

July 7, 2021

Ischemix, Inc. Receives US Department of Defense Funding of $2.9 million to Conduct Phase 1 Study of Drug Candidate to Treat Traumatic Brain Injury (TBI)

March 25, 2019

Novel Compound for Treatment of Traumatic Brain Injury (TBI) Demonstrates Positive Results in a Preclinical Study

April 4, 2016

Ischemix Announces Results of Its Phase 2 CARIN Trial

January 5, 2016

Ischemix, Inc. to Present at Biotech Showcase™ on January 13, 2016

December 9, 2015

Ischemix, Inc. Announces First International Patent Coverage of Novel Analogs of its Lead Cytoprotective Compound

September 30, 2015

Ischemix, Inc. Completes Enrollment of Phase 2 Trial for Prevention of Acute Kidney Injury and Cardiac Injury in Cardiac Catheterization Patients

August 12, 2015

Ischemix Elects Peter G. Milner, MD to Board of Directors

May 19, 2015

Safety Review Committee for CARIN Trial recommends Phase 2a study to continue as planned

March 24, 2015

Ischemix Appoints Clinical Trial Liaison

June 26, 2014

Ischemix Enrolls First Patient in Phase 2a Trial to Prevent Contrast-Induced Acute Kidney Inury

January 9, 2013

Ischemix Appoints new Chief Executive Officer

June 17, 2011

Ischemix Completes Phase 2a Clinical Trial

March 2, 2011

Ischemix Granted Composition of Matter Patent for CMX-2043

March 9, 2010

Ischemix Initiates Phase 2a Clinical Trial

August 13, 2007

Ischemix Completes Phase 1 Clinical Trial

April 5, 2007

Ischemix Initiates Clinical Development